The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes
Anca Pantea Stoian, Alexandros Sachinidis, Roxana Adriana Stoica, Dragana Nikolić, Angelo Maria Patti, Ali A. Rizvi
Topics & Concepts
SaxagliptinAlogliptinLinagliptinSitagliptinVildagliptinMedicineTolerabilityDipeptidyl peptidase-4Type 2 diabetesPharmacologyIncretinDiabetes mellitusDipeptidyl peptidase-4 inhibitorIntensive care medicineInternal medicineAdverse effectEndocrinologyDiabetes Treatment and ManagementNeuroendocrine Tumor Research AdvancesPeptidase Inhibition and Analysis